Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Savara Inc. (NASDAQ:SVRA) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.1429.

SVRA has been the subject of a number of recent analyst reports. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Finally, Oppenheimer initiated coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock.

Institutional Trading of Savara

Large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of Savara in the 1st quarter worth about $57,000. Russell Investments Group Ltd. lifted its position in shares of Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares during the period. Xponance LLC bought a new stake in shares of Savara during the 4th quarter valued at about $66,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Savara during the 3rd quarter valued at about $44,000. Institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

Shares of NASDAQ:SVRA opened at $5.28 on Thursday. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -9.43 and a beta of 0.24. The company has a 50-day moving average price of $5.56 and a 200-day moving average price of $5.51. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara has a 12 month low of $2.43 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, equities analysts anticipate that Savara will post -0.57 EPS for the current year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.